The role of Akkermansia muciniphila in inflammatory bowel disease: Current knowledge and perspectives

被引:77
|
作者
Zheng, Mengyu [1 ]
Han, Ran [2 ]
Yuan, Yali [2 ]
Xing, Yunqi [2 ]
Zhang, Wenji [2 ]
Sun, Zhongmei [3 ]
Liu, Yuyue [2 ]
Li, Junxiang [2 ]
Mao, Tangyou [2 ]
机构
[1] Univ Bristol, Bristol, England
[2] Beijing Univ Chinese Med, Dongfang Hosp, Beijing, Peoples R China
[3] Tianjin Nankai Hosp, Tianjin, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 13卷
基金
美国国家科学基金会;
关键词
Akkermansia muciniphila; inflammatory bowel disease; barrier function; mucosal immunity; gut microbiota; ULCERATIVE-COLITIS; INSULIN-RESISTANCE; GUT MICROBIOTA; MUCIN; COLONIZATION; METABOLITES; PROBIOTICS; ABUNDANCE; PROTECTS; BACTERIA;
D O I
10.3389/fimmu.2022.1089600
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, is a chronic relapsing gastrointestinal inflammatory disease mediated by dysregulated immune responses to resident intestinal microbiota. Current conventional approaches including aminosalicylates, corticosteroids, immunosuppressive agents, and biological therapies are focused on reducing intestinal inflammation besides inducing and maintaining disease remission, and managing complications. However, these therapies are not curative and are associated with various limitations, such as drug resistance, low responsiveness and adverse events. Recent accumulated evidence has revealed the involvement of mucin-degrading bacterium Akkermansia muciniphila (A. muciniphila) in the regulation of host barrier function and immune response, and how reduced intestinal colonisation of probiotic A. muciniphila can contribute to the process and development of inflammatory bowel diseases, suggesting that it may be a potential target and promising strategy for the therapy of inflammatory bowel disease. In this review, we summarise the current knowledge of the role of A. muciniphila in IBD, especially focusing on the related mechanisms, as well as the strategies based on supplementation with A. muciniphila, probiotics and prebiotics, natural diets, drugs, and herbs to promote its colonisation in the gut, and holds promise for A. muciniphila-targeted and -based therapies in the treatment of inflammatory bowel disease.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] Imaging in inflammatory bowel disease: current and future perspectives
    Shaban, Nader
    Hoad, Caroline L.
    Naim, Iyad
    Alshammari, Meshari
    Radford, Shellie Jean
    Clarke, Christopher
    Marciani, Luca
    Moran, Gordon
    FRONTLINE GASTROENTEROLOGY, 2022, 13 (E1) : E28 - E34
  • [32] Development of Akkermansia Muciniphila Membrane-Coated Mesoporous Silica Nanoparticles with a Cerium Oxide Core for Inflammatory Bowel Disease Treatment
    Zhang, Nianhua
    Zhang, Xu
    Li, Jiulong
    Li, Baoyi
    Wang, Shuai
    Liu, Xiao
    Meng, Huan
    Zhu, Motao
    ADVANCED HEALTHCARE MATERIALS, 2025,
  • [33] Revisiting the role of Akkermansia muciniphila as a therapeutic bacterium
    Si, Jiyeon
    Kang, Hyena
    You, Hyun Ju
    Ko, GwangPyo
    GUT MICROBES, 2022, 14 (01)
  • [34] Role of glucagon-like peptides in inflammatory bowel diseases—current knowledge and future perspectives
    Hubert Zatorski
    Maciej Sałaga
    Jakub Fichna
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392 : 1321 - 1330
  • [35] The role of Akkermansia muciniphila in obesity, diabetes and atherosclerosis
    Hasani, Alka
    Ebrahimzadeh, Saba
    Hemmati, Fatemeh
    Khabbaz, Aytak
    Hasani, Akbar
    Gholizadeh, Pourya
    JOURNAL OF MEDICAL MICROBIOLOGY, 2021, 70 (10)
  • [36] The potential role of Akkermansia muciniphila in liver health
    Zhang, Min
    Wang, Yang
    Gan, Yong
    FUTURE MICROBIOLOGY, 2024, 19 (12) : 1081 - 1096
  • [37] Potential Effects of Akkermansia Muciniphila in Aging and Aging-Related Diseases: Current Evidence and Perspectives
    Zeng, Shi-Yu
    Liu, Yi-Fu
    Liu, Jiang-Hua
    Zeng, Zhao-Lin
    Xie, Hui
    Liu, Jiang-Hua
    AGING AND DISEASE, 2023, 14 (06): : 2015 - 2027
  • [38] Role of glucagon-like peptides in inflammatory bowel diseases-current knowledge and future perspectives
    Zatorski, Hubert
    Salaga, Maciej
    Fichna, Jakub
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2019, 392 (11) : 1321 - 1330
  • [39] Combination therapy in inflammatory bowel disease: Current evidence and perspectives
    Dai, Cong
    Huang, Yu-Hong
    Jiang, Min
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 114
  • [40] Gut microbiota and inflammatory bowel disease:The current status and perspectives
    Lie Zheng
    Xin-Li Wen
    World Journal of Clinical Cases, 2021, 9 (02) : 321 - 333